Studie for å evaluere uønskede hendelser, endring i sykdomsaktivitet og hvordan oral ABBV-101 beveger seg gjennom kroppen hos voksne deltakere med B-celle malignitet
Første-i-menneske-studie for å evaluere sikkerheten, farmakokinetikken og den foreløpige effekten av BTK Degrader, ABBV-101, hos deltakere med B-celle maligniteter
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed.
ABBV-101 is an investigational drug being developed for the treatment of NHL. This study is a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101. Approximately 200 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide.
Participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 88 month study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network_Princess Margaret Cancer Centre /ID# 253483
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 3E4
- Centre Hospitalier De L'Universite De Montreal - Hopital Saint-Luc /ID# 253428
-
-
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85711
- Arizona Oncology - Tucson - Wilmot Road /ID# 252351
-
-
California
-
Orange, California, Forente stater, 92868-3201
- UC Irvine Medical Center /ID# 263020
-
Palo Alto, California, Forente stater, 94304
- Stanford University - Palo Alto /ID# 249683
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Rocky Mountain Cancer Centers - Aurora /ID# 252237
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 249347
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215-5400
- Beth Israel Deaconess Medical Center /ID# 249302
-
-
New Jersey
-
New Brunswick, New Jersey, Forente stater, 08901
- Rutgers Cancer Institute of New Jersey /ID# 249323
-
-
New York
-
Albany, New York, Forente stater, 12206-5013
- New York Oncology Hematology - Albany Cancer Center /ID# 252240
-
Lake Success, New York, Forente stater, 11042
- Northwell Health - Monter Cancer Center /ID# 250422
-
Rochester, New York, Forente stater, 14642-0001
- University of Rochester Medical Center /ID# 249324
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267-2827
- University of Cincinnati /ID# 249299
-
-
Oregon
-
Eugene, Oregon, Forente stater, 97401-6036
- Oncology Assoc. of Oregon PC - WVCI and Research Ctr - Springfield /ID# 249309
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 250341
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- MD Anderson Cancer Center /ID# 249293
-
-
-
-
-
Paris, Frankrike, 75010
- Hopital Saint-Louis /ID# 253663
-
-
Gironde
-
Bordeaux, Gironde, Frankrike, 33000
- Institut Bergonie /ID# 253664
-
-
Herault
-
Montpellier, Herault, Frankrike, 34295
- CHU Montpellier - Hopital Saint Eloi /ID# 253666
-
-
Nord
-
Lille, Nord, Frankrike, 59037
- CHRU Lille - Hopital Claude Huriez /ID# 253665
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Frankrike, 44000
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 256248
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, Frankrike, 94805
- Institut Gustave Roussy /ID# 253662
-
-
-
-
Central District
-
Tsrifin, Central District, Israel, 70300
- Yitzhak Shamir Medical Center /ID# 254566
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 91120
- Hadassah Medical Center-Hebrew University /ID# 251123
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israel, 5265601
- The Chaim Sheba Medical Center /ID# 251122
-
Tel Aviv, Tel Aviv, Israel, 6423906
- Tel Aviv Sourasky Medical Center /ID# 259608
-
-
-
-
-
Bergamo, Italia, 24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII /ID# 260317
-
Bologna, Italia, 40138
- IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255172
-
-
Milano
-
Milan, Milano, Italia, 20132
- IRCCS Ospedale San Raffaele /ID# 253531
-
Milan, Milano, Italia, 20162
- ASST Grande Ospedale Metropolitano Niguarda /ID# 253532
-
-
Piedmont
-
Turin, Piedmont, Italia, 10126
- A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 253530
-
-
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- National Cancer Center Hospital East /ID# 250684
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 606-8507
- Kyoto University Hospital /ID# 261837
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
- National Cancer Center Hospital /ID# 250680
-
Koto-ku, Tokyo, Japan, 135-8550
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 260375
-
-
-
-
-
Barcelona, Spania, 08035
- Hospital Universitario Vall de Hebron /ID# 260447
-
Madrid, Spania, 28034
- Hospital Universitario Ramon y Cajal /ID# 260450
-
Madrid, Spania, 28040
- Hospital Universitario Fundacion Jimenez Diaz /ID# 253654
-
Madrid, Spania, 28050
- Hospital Universitario HM Sanchinarro /ID# 253655
-
Salamanca, Spania, 37711
- Hospital Universitario de Salamanca /ID# 253656
-
-
Madrid
-
Majadahonda, Madrid, Spania, 28222
- Hospital Universitario Puerta de Hierro - Majadahonda /ID# 260196
-
-
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Storbritannia, CB2 2QQ
- Addenbrookes Hospital /ID# 256242
-
-
England
-
Leicester, England, Storbritannia, LE1 5WW
- Leicester Royal Infirmary /ID# 255171
-
-
Greater London
-
London, Greater London, Storbritannia, SE5 9RS
- Kings College Hospital NHS Foundation Trust /ID# 253670
-
London, Greater London, Storbritannia, NW1 2BU
- UCLH NHS FT - University College Hospital /ID# 260202
-
-
-
-
-
Berlin, Tyskland, 12203
- Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 257431
-
Hamburg, Tyskland, 20246
- Universitaetsklinikum Hamburg-Eppendorf /ID# 264566
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Tyskland, 89081
- Universitaetsklinikum Ulm /ID# 253742
-
-
Bavaria
-
Würzburg, Bavaria, Tyskland, 97080
- Universitaetsklinikum Wuerzburg /ID# 254636
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Tyskland, 18057
- Universitaetsmedizin Rostock /ID# 259657
-
-
Saarland
-
Homburg, Saarland, Tyskland, 66424
- Universitaetsklinikum des Saarlandes /ID# 257435
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
For Dose Escalation only (including backfill): Participants have received at least two prior systemic therapies, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), have measurable disease requiring treatment, and have a documented diagnosis for one of the following third line or later B-cell malignancies, from one of the following world health organization (WHO)-defined histologies (Swerdlow et al 2016):
-
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- For Dose Escalation backfill only - Bruton's tyrosine kinase inhibitor (BTKi)/Bruton's tyrosine kinase degrader (BTKd)-naïve CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received at least one prior systemic therapy that cannot be a BTK inhibitor or degrader, and, with the exception of BTK pathway agents, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
- For Dose Escalation backfill only - BTKi/BCL-2i combination regimen-exposed 2L CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received one prior systemic therapy with a BTKi and BCL-2i combination regimen, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
-
Chimeric antigen receptor T-cells (CAR-T)/hematopoietic cell transplant (HCT) relapsed/refractory (R/R) or ineligible diffuse large b-cell lymphoma (DLBCL) from the following histologies: DLBCL not otherwise specified (NOS) (germinal center B cell [GCB] and non-GCB DLBCL), T-cell/histiocyte-rich large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell lymphoma NOS.
-
Mantle cell lymphoma (MCL)
-
Follicular lymphoma [FL] (grades 1-3b)
-
Marginal zone lymphoma [MZL] (splenic, extranodal, and nodal)
-
Waldenström macroglobulinemia (WM)
-
Transformed indolent non-Hodgkin's lymphoma (iNHL)
-
-
Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2. For EU only: Participant has an ECOG PS of 0 or 1.
-
Participant has a life expectancy >= 12 weeks.
-
Prior Bruton's tyrosine kinase inhibitor (BTKi) is allowed.
-
Adequate hematologic, renal, and hepatic function per the protocol.
Exclusion Criteria:
- Previously treated with a Bruton's tyrosine kinase (BTK) degrader, except ABBV-101.
- Known active central nervous system (CNS) disease, or primary CNS lymphoma. Participants with prior CNS disease that have been effectively treated may be eligible.
- Uncontrolled active systemic infection requiring systemic treatment that is ongoing or was completed <= 14 days before the first dose of study drug, or active cytomegalovirus infection.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Dose Escalation: ABBV-101
Participants with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) will receive escalating doses of ABBV-101, until the maximum administered dose (MAD)/Maximum tolerated dose (MTD) is determined, as part of the approximately 88 month study duration. |
Oral:Tablet |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Adverse Events (AE)
Tidsramme: Up to Approximately 88 Months
|
AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 88 Months
|
|
Change in Laboratory Parameters
Tidsramme: Up to Approximately 88 Months
|
Number of participants with clinically significant change from baseline in clinical laboratory test results like hematology will be reported. |
Up to Approximately 88 Months
|
|
Change in Vital Signs
Tidsramme: Up to Approximately 88 Months
|
Number of participants with clinically significant change from baseline in vital signs like systolic and diastolic blood pressure will be reported. |
Up to Approximately 88 Months
|
|
Change in Electrocardiogram (ECG)
Tidsramme: Up to Approximately 88 Months
|
12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration. |
Up to Approximately 88 Months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum Observed Serum Concentration (Cmax) of ABBV-101
Tidsramme: Up to Approximately 88 Months
|
Maximum observed serum concentration of ABBV-101. |
Up to Approximately 88 Months
|
|
Time to Cmax (Tmax) of ABBV-101
Tidsramme: Up to Approximately 88 Months
|
Time to Cmax of ABBV-101. |
Up to Approximately 88 Months
|
|
Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-101
Tidsramme: Up to Approximately 88 Months
|
Area under the serum concentration versus time curve (AUC) of ABBV-101. |
Up to Approximately 88 Months
|
|
Number of Participants with Response of Partial Response (PR) or Better Response (Overall Response) per Disease-Specific Criteria
Tidsramme: Up to Approximately 88 Months
|
Number of participants with response of PR or better response (overall response) per disease-specific criteria. |
Up to Approximately 88 Months
|
|
Duration of Response (DOR)
Tidsramme: Up to Approximately 88 Months
|
DOR is defined for participants achieving PR or better as the time from the initial response per Investigator review to disease progression or death of any cause, whichever occurs earlier. |
Up to Approximately 88 Months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: ABBVIE INC., AbbVie
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- Follikulært lymfom (FL)
- Kronisk lymfatisk leukemi (KLL)
- Lite lymfatisk lymfom (SLL)
- Hematopoetisk celletransplantasjon (HCT)
- Mantelcellelymfom (MCL)
- Marginal sone lymfom (MZL)
- Hematologisk kreft
- Chimeric antigen reseptor T-celler (CAR-T)
- Waldenström makroglobulinemi (WM)
- Transformert indolent non-Hodgkins lymfom (INHL)
- ABBV-101
- Relapsed/refractory (R/R) or ineligible Diffuse large B-cell lymphoma (DLBCL)
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Neoplasmer etter nettsted
- Neoplasmer
- Kronisk sykdom
- Sykdomsattributter
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Leukemi, B-celle
- Lymfom, B-celle
- Lymfom
- Neoplasmer, plasmacelle
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Hemoragiske lidelser
- Leukemi, lymfoid
- Leukemi
- Patologiske tilstander, tegn og symptomer
- Hemic og lymfatiske sykdommer
- Tilbakefall
- Hematologiske neoplasmer
- Leukemi, lymfatisk, kronisk, B-celle
- Lymfom, follikulær
- Lymfom, mantelcelle
- Waldenstrom makroglobulinemi
- Lymfom, B-celle, Marginal sone
Andre studie-ID-numre
Andre studie-ID-numre
- M23-647
- 2023 (U.S. NIH-stipend/kontrakt)
- 2023-503594-38-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .